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SUMMARY 
 
 Signaling diversity and subsequent complexity in higher eukaryotes is partially explained 
by one gene encoding a polypeptide with multiple biochemical functions in different cellular 
contexts. For example, mouse double minute 2 (MDM2) is functionally characterized as both an 
oncogene and tumor suppressor, yet this dual classification confounds the cell biology and 
clinical literatures. Identified via complementary biochemical, organellar, and cellular 
approaches, we report that MDM2 negatively regulates NADH:ubiquinone oxidoreductase 75 
kDa Fe-S protein 1 (NDUFS1), leading to decreased mitochondrial respiration, marked oxidative 
stress, and commitment to the mitochondrial pathway of apoptosis. MDM2 directly binds and 
sequesters NDUFS1 preventing its mitochondrial localization, ultimately causing Complex I and 
supercomplex destabilization, and inefficiency of oxidative phosphorylation. The amino terminal 
region of MDM2 is sufficient to bind NDUFS1, alter supercomplex assembly, and induce 
apoptosis. Finally, this pathway is independent of p53, and several mitochondrial phenotypes are 
observed in Drosophila and murine models expressing transgenic Mdm2.  
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INTRODUCTION 
 
Using two distinct promoters and twelve exons, the Mdm2 gene produces a host of 
mRNA transcripts leading to the expression of full-length wild-type MDM2 and multiple 
disease-related isoforms (Fakharzadeh et al., 1991; Momand et al., 1992; Iwakuma and Lozano 
2003; Vousden and Prives 2005; Singh et al., 2009; Jeyaraj et al., 2009). The wild-type 90-kDa 
MDM2 protein contains motifs that are essential for its function, including: nuclear localization 
and nuclear export signals (NLS and NES), a central core consisting of an acidic region and a 
zinc finger domain, and a carboxyl terminus RING finger, which is responsible for an E3 
ubiquitin ligase activity (Tan et al., 2017). Together, these attributes define a complex network of 
subcellular localizations, diverse binding partners, and post-translational modifications that 
affect and effect MDM2 signaling (Manfredi, 2010). 
Early studies on MDM2 highlighted the fundamental observation that MDM2 levels in 
human tumor samples range from 5 – 50 fold over basal expression suggesting an oncogenic role 
by blocking p53 function (Oliner et al., 1992; Bueso-Ramos et al., 1993; Bueso-Ramos et al., 
1995; Bueso-Ramos et al., 1996). In contrast, a tumor suppressor activity was revealed in 
primary tissues as transgenic Mdm2 mice expressing just two fold over physiological levels were 
challenging to generate (Jones et al., 1998). Curiously, transgenic Mdm2 mice demonstrate dose-
dependent susceptibility to tumor burden: animals expressing two copies of the Mdm2 transgene 
have shorter tumor-free survival compared to a single copy of the transgene, and the tumor 
spectrum greatly differs from trp53-/- mice (Jones et al., 1998). In situ functional dissection 
between MDM2 and p53 is also suggested by the observation that human tumors can harbor both 
MDM2 over-expression and mutant p53. A short time after MDM2 was described to have an 
oncogenic function, several studies revealed that MDM2 over-expression correlated with poor 
patient prognosis in multiple cancer types (Reifenberger et al., 1993; Matsumura et al., 1996). 
However, few studies provide mechanistic insights into how MDM2 signaling disrupts cellular 
homeostasis beyond direct links to DNA metabolism and the p53 pathway (Saadatzadeh et al., 
2017). Here, we show that cytosolic MDM2 binds and sequesters a component of Complex I, 
NDUFS1 (NADH:ubiquinone oxidoreductase 75 kDa Fe-S protein 1), which leads to a loss in 
mitochondrial bioenergetics, marked reactive oxygen species generation, and in several cellular 
models, commitment to the mitochondrial pathway of apoptosis. 
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RESULTS 
 
 MDM2 regulates cellular survival independent of its canonical functions. Based on the 
above literature, we hypothesized that MDM2 may promote signaling that is either incompatible 
with homeostasis (i.e., tumor suppressor function) --- and/or facilitates cellular transformation 
(i.e., oncogenic function) --- by selecting for apoptosis-incompetent cells. To examine this 
hypothesis in the absence of confounding p53-mediated effects, we evaluated ectopic MDM2 
expression in a functionally-null p53 deficient human non-small cell lung cancer cell line, 
H1299. First, H1299 were transiently transfected with increasing amounts of Mdm2 cDNA, and 
this led to dose-dependent cell death within 48 hours (Fig. 1A). MDM2 has two well-defined 
features: (1) it functions in association with its binding partner, MDMX; and (2) a robust E3 
ubiquitin ligase activity (Tan et al., 2017). Therefore, we tested if either were required for 
MDM2-induced cell death. To do so, the MDMX gene was stably silenced using three shRNAs 
in H1299, and then these cells were transfected with MDM2 cDNA. Silencing of MDMX did not 
produce any significant changes in cell death responses compared to the scrambled RNAi control 
(Figs. 1B, S1A); and co-expression of MDM2 and MDMX did not alter the extent or rate of cell 
death (Figs. S1B-F). Furthermore, ectopic expression of a catalytic cysteine mutant (C464A; 
Kubbutat et al., 1999) of MDM2 that fails to function as an E3 ubiquitin ligase also induced 
potent, dose-dependent cell death responses (Figs. 1C, S1G). To determine if ectopically 
expressed MDM2 functioned as expected within the canonical p53 pathway, we also compared 
MDM2’s effects in the presence of ectopic p53. H1299 were transfected with TRP53 cDNA, 
which resulted in marked cell death; and co-expression of p53 and MDM2 or MDM2 C464A 
(binds p53 but cannot degrade) prevented the cell death responses, suggesting that transiently 
expressed MDM2 was functional (Figs. 1D, S1G-H).  
 To expand these cell death observations into additional p53 null contexts, we transiently 
transfected MDM2 into HCT116TRP53-/-, A549 with stable expression of TRP53 RNAi, and 
mouse embryonic fibroblasts (MEFs) with recombined floxed Trp53 alleles; and these cell lines 
also demonstrated dose-dependent cell death when MDM2 was expressed (Fig. 1E). We 
corroborated these results by examining a MDM2 mutant (MDM2G58A; Freedman et al., 1997) 
that fails to bind p53, and its expression also led to cell death comparable to MDM2WT (Fig. 1F). 
Based on the data in 1D, we reasoned that the p53·MDM2 complex could negatively regulate 
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MDM2-induced cell death, and disruption may reveal cell death responses. To examine this 
possibility, we compared two human non-small cell lung cancer lines: H460 and H23, which 
express p53WT or a structural mutant of p53 that fails to bind DNA and induce pro-apoptotic 
transcriptional responses (p53R246I), respectively. These cell lines were transiently transfected 
with MDM2, and then treated with Nutlin-3A, a small molecule that disrupts the p53·MDM2 
complex (Vassilev et al., 2004). While MDM2WT expression or Nutlin-3A treatment alone did 
not influence cell survival in the presence of endogenous p53, the combination promoted 
equivalent cell death in both lines further suggesting the cellular response to MDM2 was not 
likely mediated by p53-dependent transcription (Fig. 1G). Finally, the above studies focused on 
transient expression of MDM2, and therefore we were interested in extending these 
investigations by using a doxycycline-inducible MDM2 system. H1299 with stable MDM2TetOn 
were treated with doxycycline, and assayed for cell death. Similar to our results with transient 
models (Figs. 1A-G), induction of MDM2 protein led to time-dependent cell death that peaked 
around 48 hours (Figs. 1H-I). These observations suggest that MDM2 promotes cell death 
independent of its well-described functions. 
  
 MDM2-induced cell death is engaged by the mitochondrial pathway of apoptosis. As 
murine (MDM2) and human MDM2 (HDM2) proteins are 80% conserved, we determined if they 
produced comparable cell death results. Indeed, H1299 expressing either MDM2 or HDM2 
resulted in marked cell death (Fig. 2A), and subsequent cell death assays, we primarily focused 
on MDM2, but corroborated the key findings using HDM2 (data not shown). Multiple 
mechanisms control cell death, and we next defined the signaling pathway required for MDM2-
induced death. First, we examined the morphology of DAPI-stained nuclei from cells that died 
following MDM2 expression, and marked nuclear fragmentation was apparent suggesting 
apoptosis as the mechanism of death (Fig. 2B). To determine if this was correct, we performed 
kinetic cell death analysis using live-cell high-content imaging of H1299 expressing MDM2 in 
the presence of zVAD-fmk, an irreversible inhibitor to the apoptotic caspases. While MDM2 
induced dose- and time-dependent death, nearly all of this death was blocked by zVAD-fmk 
(Figs. 2C-D). Cells marked as dead in these assays led to a loss of clonogenic survival (Fig. 2E), 
and death was not prevented by the co-expression of a dominant negative FADD (which inhibits 
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death receptor induced apoptosis; Fig. 2F), suggesting the mitochondrial pathway of apoptosis is 
induced by MDM2.  
 The BCL-2 family is the key mediator of the mitochondrial pathway of apoptosis by 
regulating mitochondrial outer membrane permeabilization (MOMP), caspase activation, and 
irreversible commitment to death (Chipuk et al., 2010). We screened whole cell lysates from 
H1299 expressing MDM2 for changes to BAK, BAX, and BIM, which are the BCL-2 family 
effectors and a BH3-only protein that collaborate to engage the majority of stress-induced 
apoptosis; but no gross changes were apparent (Fig. 2G); and mRNA changes were also not 
observed (data not shown). As BIM is the critical BH3-only protein that functions at 
mitochondria to activate BAK/BAX leading to apoptosis, we next determined if BIM was 
localized to mitochondria following MDM2 expression. H1299 cells were transfected with 
MDM2 in the presence of zVAD-fmk to prevent death, whole cell and mitochondrial extracts 
were isolated, and analyzed by SDS-PAGE and western blot for BIM. MDM2 caused the 
accumulation of the short isoform of BIM (BIM-S) within the mitochondrial fraction (Fig. 2H); 
and RNAi-mediated silencing of BIM maintained survival of MDM2-expressing cells (Figs. 2I, 
S2A). The pro-apoptotic function of BIM is to activate BAX and/or BAK; therefore, we tested if 
knockdown of BAX or BAK also promoted survival. Indeed, RNAi mediated silencing of BAX or 
BAK resulted in rescue from MDM2-induced death (Figs. 2J, S2B, S2D-G); and this paralleled 
activation-induced conformational changes in BAX (Fig. S2C), while silencing other BH3-only 
proteins (e.g., BID & PUMA) did not alter MDM2-induced death (Figs. S2D-G). Next, we 
examined the impact of anti-apoptotic BCL-2 (e.g., BCL-xL, MCL-1) proteins to regulate 
MDM2-induced death. H1299 expressing MDM2 alone, or in the presence of BCL-xL or MCL-
1, were analyzed for cell death. Co-expression of BCL-xL or MCL-1 inhibited cell death 
responses (Fig. 2K); and a complementary loss of function experiment with ABT-737, a small 
molecule BH3 mimetic that inhibits multiple anti-apoptotic BCL-2 proteins resulted in enhanced 
death (Oltersdorf  et al.,  2005; Fig. 2L). Together, these data suggest that the mitochondrial 
pathway of apoptosis mediates MDM2-induced death. 
 To explore the greater impact of MDM2-induced apoptosis in cell biology, we utilized 
Drosophila melanogaster expressing MDM2 under control of the GAL4/UAS system, which 
allows for tissue-specific expression, and is temperature sensitive to allow increased expression 
at higher temperatures (Folberg-Blum et al., 2002). We chose Drosophila because they have 
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conserved stress signaling and cell death pathways; yet, the Drosophila p53 pathway is not 
regulated by mammalian MDM2, and there is no Drosophila MDM2 homolog to confound 
interpretations. As shown in figure 2M, Drosophila expressing MDM2 in the eye 
(GMR>MDM2)  at 21C demonstrate cellular stress revealed by smaller, rough, less organized 
eye tissue that is dependent upon gene dosage; and temperature-dependent increased expression 
of MDM2 led to dose-dependent tissue ablation (Figs. S2H-I). When GMR>MDM2 animals 
were crossed against strains that genetically disable cellular commitment to apoptosis (H99, a 
deletion that eliminates reaper/grim/hid to prevent the initiation of apoptotic signaling; 
transgenic DIAP1 or p35, suppress caspase activation; Davidson et al., 1998; White et al., 1994), 
the majority of MDM2-induced eye phenoytpes were suppressed (Fig. 2N). Similar results were 
also obtained using a wing-specific promoter (Fig. S2J). Moreover, 96.8% of GMR>MDM2 flies 
reared at 30C failed to eclose suggesting marked developmental abberations, but when crossed 
into apoptosis-deficient backgrounds, flies successfully eclosed at rates approaching Mendelian 
ratios (Fig. 2O). These results suggested that MDM2-induced stress and subsequent apoptotic 
responses are observable in numerous cell types and tissues. 
  
 The MDM2 amino terminal domain (amino acids 1-101) is sufficient to promote the 
mitochondrial pathway of apoptosis and causes genomic and oxidative stress. MDM2 has 
several functional domains, and we examined which was required for MDM2-induced apoptosis 
(Fig. 3A). H1299 were transfected with the indicated truncated versions of MDM2, and scored 
for apoptosis. MDM21-227 was the most potent mediator of cell death (Fig. 3B), its expression 
level was similar to the other MDM2 variants (Fig. 3C), and the observed death was regulated by 
zVAD-fmk, ABT-737, and BCL-xL as predicted suggesting MDM21-227 also induced the 
mitochondrial pathway of apoptosis (Figs. 3D-E). Moreover, we generated further deletions of 
MDM2 (data not shown), and narrowed down a minimal amino terminal 101 amino acid region 
(MDM21-101) that was a potent-inducer of dose-dependent apoptosis (Fig. 3F).  
 To better understand MDM2 initiated stress and subsequent apoptosis, we explored how 
MDM2 localization impacted on cell death. First, we determined MDM2WT and MDM21-101 
localization by immunofluorescence, as they both are potent inducers of apoptosis. Ectopic 
expression of these untagged proteins was detected throughout the cell, with relatively similar 
nuclear and cytosolic distributions (Fig. 3G). As such, we then compared how mutation of the 
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nuclear localization signal (NLS-) and nuclear export signal (NES-) influenced apoptosis 
induced by full-length MDM2. These mutant forms of MDM2 resulted in expected cellular 
localizations: MDM2NLS- and MDM2NES- were cytosolic and nuclear, respectively (Fig. 3H); and 
their expression levels by western blot were similar to MDM2WT (Fig. 3I). Interestingly, 
MDM2WT and MDM2NLS- demonstrated equivalent dose-dependent apoptotic responses (Fig. 3J); 
MDM2NES- produced no apoptotic responses alone or when combined with ABT-737 (data not 
shown) --- and these data suggested that MDM2 stress signaling originates from the cytoplasm. 
 We screened through several macromolecular stress pathways (e.g., unfolded protein 
response, oxidative damage, and DNA damage) and noted that H1299 cells expressing MDM2WT 
or MDM21-101 demonstrated marked nuclear H2AX accumulation (Fig. 3K) and Chk1Ser345 
phosphorylation (Fig. 3L), two markers of DNA damage and downstream double strand break 
signaling. In addition, we analyzed metaphase spreads, and noted that both MDM2WT and 
MDM21-101 expression produced severe genomic damage as evidenced by chromosome and 
chromatid breaks (Fig. 3M). Continued screening also revealed that MDM2WT and MDM21-101 
expression also resulted in marked cellular ROS production (Fig. 3N), which upon further 
examination, was likely mitochondrial in origin as ROS was detected by a mitochondrial-specific 
probe (MitoSOX, Fig. 3O). In experiments not shown, we could not detect activation of the 
unfolded protein response. These observations served as the basis that MDM2 expression results 
in mitochondrial ROS production, DNA damage, and subsequent apoptosis.  
 
 MDM2 binds NDUFS1 to destabilize supercomplex-assembled Complex I and promote 
ROS. As mitochondrial ROS is produced by the electron transport chain (ETC), we examined 
how MDM2 influenced mitochondrial respiration. H1299 expressing either MDM2WT, 
MDM2NLS-, or MDM21-101 were subjected to Seahorse MitoStress analysis, and these MDM2 
variants which demonstrate cytosolic accumulation also reduced basal and maximal oxygen 
consumption rates (OCR; Figs. 3G-H, 4A, S3A); whereas cells expressing MDM2NES-, which is 
restricted to the nucleus (Fig. 3H), did not reduce cellular respiration (Fig. 4A) or commit cells to 
undergo apoptosis (Fig. 3J). Interestingly, the MDM21-101-dependent decrease in cellular 
respiration was not prevented by co-treatment with SOD1 (a copper-zinc dependent enzyme 
localized to both the cytosol and mitochondrial inner-membrane space that resolves ROS by 
converting them to hydrogen peroxide; Che et al., 2016) or MitoQ (mitochondrially-targeted 
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small molecule anti-oxidant; Murphy 2016), suggesting MDM2-induced alterations in 
mitochondrial respiration were upstream of ROS production (Figs. 4B-C). Since the above relied 
upon exogenous MDM2, we next compared two human osteosarcoma cell lines with either 
normal (U-2 OS) or amplified (SJSA-1) MDM2 levels (Fig. S3B) for changes in mitochondrial 
respiration due to pharmacological regulation of MDM2. U-2 OS do not constitutively express 
detectible MDM2 protein, and therefore, short term (24 h) treatment with Nutlin-3A did not 
impact on mitochondrial respiration (Figs. 4D & 4F). In contrast, SJSA-1 constitutively express 
MDM2, demonstrate markedly less mitochondrial respiration compared to U-2 OS, and 
basal/maximal respiratory rates were further decreased by the addition of Nutlin-3A 
independently of apoptosis as zVAD-fmk treatment did not rescue the loss (n.b., Nutlin-3A 
treatment did not cause detectible cell death in short term assays) (Figs. 4E-4F). We noted that a 
longer (48 h) Nutlin-3A treatment of U-2 OS cells resulted in detectible MDM2 protein and a 
reduction in basal and maximal respiration (Figs. S3C-G). These data suggest: (1) MDM2 
disrupts mitochondrial respiration; and (2) Nutlin-3A could promote MDM2-dependent effects 
on mitochondrial respiration (Figs. 4A-F) and cell death (Fig. 1G). 
 Next, the literature was searched for potential insights to mechanistically unite these 
observations. We noted a publication that catalogued MDM2-interacting proteins, which also 
included a description of Nutlin-3A sensitive MDM2-interacting proteins (Nicholson et al., 
2014). Specific to our study, the authors described that NDUFS1 (NADH:ubiquinone 
oxidoreductase 75 kDa Fe-S protein 1; Janssen et al., 2006) was a potential MDM2-interacting 
protein, and this interaction was potentially enhanced by Nutlin-3A. NDUFS1 contains three Fe-
S clusters and participates in the entry and efficiency of electron (e-) transfer within the 
NADH:dehyrogenase (N) module of Complex I (CI); and NDUFS1 also participates in 
supercomplex assembly with Complex III (CIII). Inspection of the NDUFS1 protein revealed an 
alpha helical domain with similiarities to how p53 binds MDM2. Using PyMOL, we created a 
hybrid NDUFS1/p53 domain in association with MDM2 to gain perspectives to the Nutlin-3A 
regulation (Fig. 4G), and the identification of MDM2 mutants for subsequent experiments. 
Previous experiments in figure 3 suggest that the MDM2 biology under investigation originates 
from within the cytosol, so we transfected H1299 with MDM2, isolated cytosolic fractions, and 
determined effects on NDUFS1. The cytosol normally has minimal NDUFS1, as once this 
nuclear-encoded mitochondrial protein is transcribed and translated, NDUFS1 is imported into 
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mitochondria. Interestingly, we noted a positive correlation between cytosolic MDM2 levels and 
endogenous NDUFS1 accumulation in the cytosol (Fig. 4H). Direct interactions between MDM2 
and NDUFS1 were next determined using four approaches: (i) MDM2WT was transfected into 
H1299, cytosolic and nuclear extracts were prepared, subjected to anti-MDM2 
immunoprecipitation, and probed for endogenous NDUFS1; (ii) endogenous NDUFS1 was 
immunopurified from H1299, GST-MDM2WT or GST-MDM21-101 was added, washed, and 
probed for NDUFS1-associated MDM2; (iii) endogenous cytosolic NDUFS1 was 
immunopurified from SJSA-1 cells, and probed for endogenous MDM2; and (iv) recombinant 
MDM2 binding to recombinant NDUFS1 was determined by microscale thermophoresis. 
Together, the results from these experiments demonstrated that MDM2 directly binds to 
NDUFS1 with an apparent affinity of KD = 1.1  0.6 M  (Figs. 4I-L), which promotes NDUFS1 
accumulation in the cytosol; and Nutlin-3A could enforce the interaction between MDM2 and 
NDUFS1. As the MDM2 interface with NDUFS1 was predicted on p53 binding, we also tested if 
p53 could displace NDUFS1 from MDM2, and observed dose-dependent release of NDUFS1 
from MDM2 (Figs. S4A-D). 
 A mechanistic link between NDUFS1 and cellular stress leading to MDM2-dependent 
apoptosis is not described. Here, we hypothesized that MDM2-bound NDUFS1 provokes CI 
dysfunction leading to apoptosis. To test this hypothesis, we first examined the cellular 
consequences of NDUFS1 loss-of-function by reducing its expression by shRNA (Fig. 4M; two 
shRNAs were analzyed and combined); and indeed, this lead to marked decreases in 
mitochondrial OCR (Fig. 4N), increased mtROS production (Fig. 4O, top panel), and the 
induction of apoptosis (Fig. 4O, bottom panel). Based on the PyMOL structure in figure 4G, we 
generated a series of MDM2 mutants predicted to bind NDUFS1 with decreased affinity: MDM2 
G58V, G58L, G58I, and G58F. Transient expression of the MDM2G58 mutants revealed that 
MDM2G58I was less efficient at binding to NDUFS1 and promoting apoptosis, despite similar 
expression and cellular localization compared to MDM2WT and other MDM2G58 mutants (Figs. 
4P-Q, S4D-F). MDM2G58I failed to promote NDUFS1 accumulation in the cytosol (Fig. S4G) 
and mtROS compared to MDM2WT, MDM21-101, and NDUFS1 RNAi (Fig. 4R); and MDM2G58I 
also demonstrated reduced binding to NDUFS1 (Figs. 4S, S4E). To broaden the context of the 
MDM2 and NDUFS1 phenotypes, we compared Drosophila expressing MDM2 or ND-75 RNAi 
(equivalent to NDUFS1) under control of a wing-specific promoter (c765gal4). Similar to the 
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eye and wing data presented in figures 2M and S2H-J, MDM2 expression caused marked 
developmental abnormalities in the wing, all of which were phenocopied by ND-75 RNAi (Fig. 
4T). Next, we examined the relationship between mtROS production, CI dysfunction, and 
H2AX staining in livers obtained from transgenic Mdm2 mice (Jones et al., 1998). Transgenic 
Mdm2 alleles promoted a gene-dosage dependent increase in mtROS and H2AX positivity, 
along with a decrease in CI activity (Fig. 4U); and similar to our cell culture experiment, 
transgenic Mdm2 expression lead to the cytosolic accumulation of NDUFS1 (Fig. 4V). Together, 
these data suggest that MDM2 regulates mtROS production by interacting with NDUFS1. 
 
 MDM2 integrates mitochondrial ROS production, genomic stress, and apoptosis 
through disruption of mitochondrial ETC efficiency. Next, we next investigated if MDM2 had 
direct effects on CI and mitochondrial respiration using two approaches: (i) GST-MDM2WT and 
GST-MDM21-101 were directly added to permeabilized H1299, and standard Seahorse-based 
MitoStress and State 3 mitochondrial respiration (ADP/Malate/Pyruvate-stimulated) were 
analyzed (Fig. 5A); and (ii) GST-MDM2WT and GST-MDM21-101 were directly added to 
digitonin-solubilized mitochondria, and CI assembly and association with CIII into 
supercomplexes (e.g., CI1+CIII2, CI2+CIII2) was analyzed (Fig. 5B). Both investigations 
suggested that MDM2 had no direct or immediate consequences on assembled CI or 
supercomplexes. Using the DOX-inducible MDM2 cellular system defined in figure 1, we 
purified and digitonin-extracted mitochondria, and analyzed supercomplex assembly and 
activity. As shown in figure 5C, the induction of MDM2 caused an appreciable decrease in both 
CI activity, and CI1/2III2 supercomplex to CI1 ratio, while non-incorporated CI and CII activities 
(for comparison) remained unaffected. Futhermore, we observed that MDM2 induction resulted 
in decreased incorporation of NDUFS1 into supercomplexes, as indicated by co-examination of 
ND1 (a mitochondrial-encoded essential CI protein); and for comparison, NDUFS1 RNAi 
produced similar observations (Fig. 5D).  
 As the loss in supercomplex-mediated CI activity could be the mechanism for MDM2-
induced apoptosis, we sought to circumvent this phenotype by sustaining high levels of overall 
CI activity with NDI1 (NADH-ubiquinone reductase H+-translocating), the single polypeptide 
yeast homolog of mammalian CI (Marres et al., 1991). First, we tested if MDM2 had general 
consequences on mitochondrial respiration in yeast. MDM2WT was stably expressed in yeast, and 
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the transformants were analyzed for growth in conditions requiring minimal (YPD) or maximal 
(YPEG) mitochondrial bioenergetics for survival (Figs. 5E-F). In all experiments, MDM2 had no 
general effect on mitochondrial respiration in yeast suggesting that additional factors (i.e., 
NDUFS1) are necessary to link MDM2 and bioenergetic consequences. Using H1299 with 
stable-expression of NDI1, as measured by increased NADH dehydrogenase activity and 
resistance to rotenone (a CI toxin; Fig. 5G), we next examined if NDI1-sustained NADH 
dehydrogenase activity was sufficient to prevent MDM2-induced apoptosis. H1299Control and 
H1299NDI1 cells were transiently transfected with increased amounts of MDM2WT, and this 
produced similar levels of MDM2 protein and apoptosis (Fig. 5H), suggesting that the overall 
decrease in CI activity caused by MDM2 was unlikely to be the direct source of cellular stress.    
 A consequence of acute CI1/2III2 supercomplex disassembly is inefficient electron 
transport and increased ROS generation (Lopez-Fabuel et al., 2016).  As this could be the 
upstream signal leading to MDM2-induced apoptosis, we examined CI dysfunction and ROS 
generation initiated by MDM2 and how the NDUFS1 binding mutant of MDM2 impacted on 
these phenotypes. Basal and State 3 OCR were compromised in the presence of MDM2WT (Figs. 
5I-J), which was associated with decreased CI1/2III2 supercomplex activity (Fig. 5K). NADH-
stimulated ROS production was highest in digitonin-extracted mitochondria and native gel-
purified CI from MDM2WT-expressing cells (Fig. 5L). In contrast, MDM2G58I failed to 
signficantly influence basal OCR, State 3 OCR,  CI1/2III2 supercomplex activity, or NADH-
stimulated ROS; and for comparison, NDUFS1 RNAi produced similar observations to 
MDM2WT in these assays (Figs. 5I-L). Finally, we examined how mitigation of MDM2-induced 
mitochondrial ROS production impacted on DNA damage and apoptosis. Therefore, we 
examined the impact of SOD1 co-expression on MDM2WT- and MDM21-101-induced 
mitochondrial ROS production, DNA damage, and subsequent apoptosis in H1299. As 
demonstrated before, MDM2WT or MDM21-101 lead to increased mitochondrial ROS, H2AX 
accumulation, and apoptosis; and co-expression of SOD1 was effective in preventing the 
majority of these stress phenotypes (Figs. 5M-O). In parallel, we examined if treatment with 
MitoQ acted similar to SOD1, and the results were comparable (Figs. 5Q-S) suggesting that the 
mitigation of MDM2-induced mitochondrial ROS prevents MDM2-induced DNA damage and 
apoptosis. To evaluate specificity for MDM2-induced apoptosis, we evaluated how SOD1 and 
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MitoQ impacted on general commitment to apoptosis (e.g., induced by staurosporine, STS), and 
no changes were observed (Figs. 5P, 5T). 
 
  
Elkholi et al., 2018                                                                                                                                               Page 15 
11/30/18 
DISCUSSION 
 
An abundance of MDM2 binding proteins, substrates for degradation, and small 
molecules targeting its function highlight the impact of MDM2 in cell biology and disease. Here, 
we describe a novel signaling network and subsequent cellular phenotypes that result from 
chronic MDM2 expression. We posit that MDM2 stabilization can lead to the cytosolic 
accumulation of NDUFS1, which destabilizes supercomplex (e.g., CI1/2+CIII2) assembly leading 
to marked mitochondrial ROS generation and decreased respiration (Figs. 4 & 5). If left 
unresolved, mitochondrial ROS can promote DNA damage eventually leading to BIM-mediated 
BAK/BAX-dependent activation of the mitochondrial pathway of apoptosis (Figs. 2 & 3). 
Cellular responses to MDM2-induced stress appear conserved across species, as developing 
Drosophila tissues, murine organs, transformed murine cell lines, and human cancer cell lines 
share similar phenotypes; and yet varied, as Drosophila tissues activate the mitochondrial 
pathway of apoptosis, similar to cultured cell lines, but murine liver appears to persist with 
minimal apoptotic responses despite increased ROS and detectable DNA damage (Figs. 2, 4, S1, 
S2). 
Several studies have highlighted the importance of gaining a broader perspective of the 
MDM2 interactome, and its regulation by small molecules like Nutlin-3A (Janssen et al., 2006; 
Way et al., 2016). MDM2 is described to bind to over 100 proteins, yet little is known about how 
all these interactions relate to the cell biology of MDM2. Small molecules targeting MDM2 alter 
the binding of its associated proteins by either directly disrupting the MDM2 interface required 
for association --- and/or --- promote numerous allosteric changes in multiple MDM2 domains 
directly, thus altering motifs to that either gain or lose capacity to interact with proteins (Janssen 
et al., 2006; Way et al., 2016). Here, we noted that Nutlin-3A could enhance the interaction 
between MDM2 and NDUFS1 (Fig. 4J), and this promoted decreased mitochondrial respiration 
in cancer cells harboring amplified MDM2 (Figs. 4D-F), and apoptosis in cells where MDM2 
was introduced transiently (Fig. 1G). Numerous mitochondrial proteins (e.g., mitochondrial 
pyruvate dehydrogenase complex) and functions (e.g., nucleotide exchange and electron 
transport) are regulated in a Nutlin-3A-dependent manner with little mechanistic or biological 
insights (Janssen et al., 2006; Way et al., 2016; Schneider et al., 2016), and there are notions in 
the literature that Nutlin-3A can regulate both cellular metabolism and signaling independent of 
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the p53 pathway (Ye et al., 2017; Fåhraeus et al., 2014). A key area of future investigation is to 
determine under which circumstances cells promote the MDM2·NDUFS1 interaction to regulate 
mitochondrial respiration, and what are the upstream signals that promote MDM2 stabilization 
and function in these settings. Moreover, a burgeoning literature shows that MDM2 can also bind 
DNA, both nuclear and mitochondrial, to control cellular metabolism and disease phenotypes, 
such as cancer metastasis (Riscal et al., 2016; Arena et al., 2018). Within figure S1E, we noted 
that MDMX expression also has a pro-apoptotic effect, while we did not investigate the causes 
and consequences of this phenotype, it is curious to note that MDM2 and MDMX share marked 
similarities at the amino terminus that may potentially suggest shared mechanisms (Karni-
Schmidt et al., 2016). 
Together, our data along with the literature reveal that a deeper mechanistic interrogation 
of MDM2 biology and its pharmacological regulation are necessary to fully appreciate the 
biological and clinical applications of this important protein and pathway. Moreover, recent 
literature reveals that MDM2-mediated signaling captures a broad spectrum of survival and 
stress pathways that likely influence its contrasting oncogenic and tumor suppressor functions. 
While the mechanisms described by us and Arena and colleagues are distinct, yet 
complementary, and p53-independent, it is becoming increasingly apparent that the p53/MDM2 
pathway has multiple intersections with numerous mitochondrial components --- adding further 
complexity, interest, and broader therapeutic potential to the oncogenic and tumor suppressor 
roles of p53 and MDM2 in health and disease. 
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FIGURE TITLES AND LEGENDS 
 
Figure 1.  MDM2 regulates cellular survival independent of its canonical functions. 
(A) H1299 were transfected with pCMV-MDM2WT (0.1, 0.25, 0.5 g), cultured for 48 hours, and 
dead cells were quantified by AnnexinV staining and flow cytometry. Whole cell lysates were 
analyzed by SDS-PAGE and western blot for indicated proteins. -Actin is the loading control.  
(B) H1299 were infected with retroviral shRNA constructs to silence MDMX, and then 
transfected with pCMV-MDM2 (0.25 g). Cell death and MDMX expression were quantified by 
flow cytometry and qPCR, respectively. 
(C) H1299 were transfected with pCMV-MDM2WT (0.1, 0.2, 0.3, 0.4, 0.5 g) or pCMV-
MDM2C464A (0.01, 0.02, 0.03, 0.04, 0.05 g), cultured for 48 hours, and evaluated as in A. N.B., 
MDM2C464A does not self-ubiquitinylate leading to constitutive degradation; therefore, ~10 less 
cDNA produces similar protein levels compared to MDM2WT. 
(D) H1299 were transfected with pcDNA3.1-p53WT and/or pCMV-MDM2WT (0.25 g each), 
cultured for 48 hours, and evaluated as in A. 
(E) Indicated cells were transfected with pCMV-MDM2WT (0.1, 0.25, 0.5 g), and evaluated as 
in A. 
(F) H1299 were transfected with pCMV-MDM2WT or pCMV-MDM2G58A (0.25 g each), 
cultured for 48 hours, and evaluated as in A. 
(G) H460 and H23 were transiently transfected with pCMV-MDM2WT (0.5 g), cultured for 24 
hours, treated with Nutlin-3A (1 M) for 48 hours, and dead cells were quantified by AnnexinV 
staining and flow cytometry. 
(H - I) H1299 stably expressing pTRE2-MDM2TetOn were treated with doxycycline (1 g/ml) for 
indicated times. Cell death and MDM2 expression were determined by flow cytometry (H) and 
western blot (I), respectively. CD95/FAS ligation with the antibody CH11 is a positive control 
for cell death. 
All data are representative of at least three independent experiments, and reported as  S.D., as 
required. 
  
Figure 2. MDM2-induced cell death is engaged by the mitochondrial pathway of apoptosis. 
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(A) H1299 were transfected with pCMV-MDM2WT or pCMV-HDM2WT (0.25 g each), cultured 
for 48 hours, and dead cells were quantified by AnnexinV staining and flow cytometry. Whole 
cell lysates were analyzed by SDS-PAGE and western blot for indicated proteins. -Actin is the 
loading control.   
(B) H1299 were transfected with pCMV-MDM2WT (0.25 g), cultured for 48 hours, and nuclei 
were labeled with DAPI before live-cell fluorescent microscopy. Scale bar = 10 m. 
(C) H1299 were transfected with pCMV-MDM2WT (0.25 g)  zVAD-fmk (100 M), and the 
kinetics of cell death were detected using an IncuCyte Zoom. 
(D) Same as C, but cells were transfected with pCMV-MDM2WT (0.1, 0.25, 0.5 g),  zVAD-
fmk (100 M), and the kinetics of cell death were detected using an IncuCyte Zoom. Endpoint 
data for 48 hours are shown.  
(E) H1299 were transfected with pCMV-MDM2WT (0.1, 0.25, 0.5 g), and colony formation was 
quantified 7 days later. 
(F) H1299 were transfected with pCMV-FADD-DN (0.5 g) and/or pCMV-MDM2WT (0.25 g), 
cultured for 48 hours, and apoptotic cells were quantified. CH11 (1 g/ml; 24 hours) was used as 
a positive control for apoptosis. 
(G) H1299 were transfected with pCMV-MDM2WT (0.1, 0.25, 0.5 g), and whole cell lysates 
were analyzed by western blot for indicated proteins.  
(H) H1299 were transfected with pCMV-MDM2WT (0.5 g), whole cell and mitochondrial 
extracts isolated, and analyzed for indicated proteins. VDAC and -Actin are the loading 
controls. 
(I - J) H1299 stably expressing BIM RNAi (I) or BAX RNAi (J) were transfected with pCMV-
MDM2WT (0.1, 0.25, 0.5 g), cultured for 48 hours, and apoptotic cells were quantified.  
(K) H1299 were transfected with pCMV-MDM2WT (0.1, 0.25, 0.5 g)  pcDNA3-hBCL-xL 
(1g) or pcDNA3.1-hMCL-1 (1 g), cultured for 48 hours, and dead cells were quantified. 
(L) H1299 were transfected with pCMV-MDM2WT (0.1, 0.25, 0.5 g)  ABT-737 (1 M), 
cultured for 48 hours, and apoptotic cells were quantified.  
(M) Representative images of Drosophila expressing transgenic MDM2 using the eye-specific 
GMRgal4. “MDM2” = 1 copy of GMR>MDM2; “MDM2 × 2” = 2 copies of GMR>MDM2;  
“Control” is GMRgal4/+. Studies were performed at 21C; female eyes are shown. 
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(N) Representative images of transgenic GMR>MDM2 flies with H99 deletion, or co-expressing 
DIAP1 or p35. Studies were performed at 25C; female eyes are shown. 
(O) Quantification of eclosed progeny from parallel crosses from M and N performed at 30C 
compared to the percent of each genotype expected for Mendelian inheritance. 
All data are representative of at least three independent experiments, and reported as  S.D., as 
required. 
 
Figure 3. The MDM2 amino terminal domain (amino acids 1-101) is sufficient to promote 
the mitochondrial pathway of apoptosis and causes genomic and oxidative stress. 
(A) Schematic of MDM2 variants used in this study. 
(B - C) H1299 were transfected with indicated MDM2 variants (0.25 g each), cultured for 48 
hours, and apoptotic cells were quantified by AnnexinV staining and flow cytometry (B). Whole 
cell lysates were analyzed by SDS-PAGE and western blot for indicated proteins. -Actin is the 
loading control (C).   
(D) H1299 were transfected with pCMV-MDM21-227 (0.5 g)  ABT-737 (1 M) or  zVAD-
fmk (100 M), cultured for 48 hours, and apoptotic cells were quantified. 
(E) H1299 were transfected with pCMV-MDM21-227 (0.5 g)  pcDNA3-hBCL-xL (1 g), 
cultured for 48 hours, and apoptotic cells were quantified. 
(F) H1299 were transfected with pCMV-MDM21-101 (0.1, 0.25, 0.5 g),  zVAD-fmk (100 M), 
cultured for 48 hours, and apoptotic cells were quantified. Whole cell lysates were analyzed by 
SDS-PAGE and western blot for indicated proteins. 
(G) H1299 were transfected with pCMV-MDM2WT or pCMV-MDM21-101 (0.25 g) in the 
presence of zVAD-fmk (100 M), cultured for 24 hours, fixed, and stained for MDM2 
localization. Scale bar = 20 m. > 200 cells were analyzed for each condition, and the % 
indicated. 
(H) Same as G, but comparing pCMV-MDM2WT, pCMV-MDM2NES-, or pCMV-MDM2NLS-. 
Scale bar = 10 m. > 200 cells were analyzed for each condition, and the % indicated. 
(I) Same as G-H, but whole cell lysates were analyzed by western blot for indicated proteins. 
(J) H1299 were transfected with pCMV-MDM2WT, pCMV-MDM2NES-, or pCMV-MDM2NLS- 
(0.25 or 0.5 g each), cultured for 48 hours, and apoptotic cells were quantified. 
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(K) H1299 transfected with pCMV-MDM2WT, pCMV-MDM2NES-, or pCMV-MDM21-101 (0.25 
g), fixed, and labeled with an H2AX antibody and DAPI. Scale bar = 10 m. > 200 cells were 
analyzed for each condition, and the % indicated. 
(L) H1299 were treated with VP16 (25 M) or transfected with pCMV-MDM21-101 (0.25 g), 
cultured for 24 hours, and harvested for western blot analysis. 
(M) H1299 were transfected with pCMV-MDM2WT or pCMV-MDM21-101 (0.25 g), and 
analyzed for metaphase spreads. Arrows indicate chromosomal aberrations. 
(N - O) H1299 were transfected with indicated MDM2 variants (0.25 g), cultured for 24 hours, 
loaded with either CellROS (1 M) or MitoSOX (5 M), analyzed by flow cytometry, and 
reported as relative fluorescent units (RFU).  
All data are representative of at least three independent experiments, and reported as  S.D., as 
required. 
 
Figure 4. MDM2 binds NDUFS1 to destabilize supercomplex-assembled Complex I and 
promote ROS. 
(A) H1299 were transfected with pCMV-MDM2WT, pCMV-MDM2NES-, pCMV-MDM2NLS-, or 
pCMV-MDM21-101 (0.25 g), cultured for 24 hours, and subjected to Seahorse XF Cell Mito 
Stress analysis.  
(B) H1299 were transfected with pCMV-MDM21-101 (0.25 g) in the presence of SOD1-GFP 
(0.25 g) or MitoQ (5 M), cultured for 24 hours, and subjected to Seahorse XF Cell Mito Stress 
analysis.  
(C) Relative basal and maximal oxygen consumption rates from B are presented. 
(D - E) U-2 OS (D) and SJSA-1 (E) cells were treated with zVAD-fmk (100 M)  Nutlin-3A (1 
M) for 24 hours, and subjected to Seahorse XF Cell Mito Stress analysis.  
(F) Relative basal and maximal oxygen consumption rates from D & E are presented. 
(G) A p53 peptide (PDB: 4hfz, residues 17-27, dark blue) was integrated within an NDUFS1 α-
helix (PDB: 5gup, residues 617-632, magenta), and complexed with MDM2 (PDB: 4hfz, 
residues 26-108, grey) using PyMOL. The NDUFS1 residues W620, K621, and I623 are 
highlighted in stick representation and form the consensus sequence for MDM2 binding. 
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(H) H1299 were transfected with pCMV-MDM2WT (0.1, 0.25, 0.5, 1 g) for 24 hours in the 
presence of zVAD-fmk (100 M), and cytosolic extracts were analyzed by SDS-PAGE and 
western blot. 
(I) H1299 were transfected with pCMV-MDM2WT (1 g) for 24 hours in the presence of zVAD-
fmk (100 M), nuclear and cytosolic extracts were subjected to anti-MDM2 
immunoprecipitation, and complexes were analyzed by western blot for indicated proteins. 
(J) Endogenous NDUFS1 was immuno-purified from H1299, GST-MDM2WT or GST-MDM21-
101 was added (0.1 g)  Nutlin-3A (1 M), incubated, washed, and the complexes were analyzed 
by western blot for indicated proteins.  
(K) Cytosolic lysates from SJSA-1 were subjected to anti-NDUFS1 immunoprecipitation, and 
complexes were analyzed by western blot for indicated proteins. 
(L) GST, GST-MDM2WT, and GST-MDM21-101 were analyzed by microscale thermophoresis for 
binding to human NDUFS1. Kd values are listed. The human p53 peptide a.a. 17 - 26 is a positive 
control for MDM2 binding. 
(M) H1299 were infected with shRNA against NDUFS1 (or control) for 96 hours. Total RNA 
and protein were analyzed by qPCR and western blot for NDUFS1 knock-down efficiency, 
respectively.  
(N) Cells in M were analyzed by Seahorse for MitoStress.  
(O) H1299 were infected with shRNA against NDUFS1 (or control) for 96 hours; and 
mitochondrial ROS production was measured with MitoSOX (top panel) or apoptotic cells were 
quantified 48 hours later (bottom panel). FCCP (1 M) is a positive control for both assays. 
(P - Q) H1299 were transfected with indicated MDM2 mutants (1 g each), cultured for 48 
hours, and apoptotic cells were quantified by AnnexinV staining and flow cytometry (P). Whole 
cell lysates were analyzed by SDS-PAGE and western blot for indicated proteins. -Actin is the 
loading control.   
(R) H1299 were infected with shRNA against NDUFS1 (or control) for 96 hours; or transfected 
with pCMV-MDM2WT or pCMV-MDM21-101 (1 g) for 48 hours in the presence of zVAD-fmk 
(100 M), mitochondrial ROS production was measured with MitoSOX and reported as relative 
fluorescent units (RFU).  
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(S) H1299 were transfected with pCMV-MDM2WT or pCMV-MDM2G58I (1 g each) for 24 
hours in the presence of zVAD-fmk (100 M), cytosolic extracts were subjected to anti-MDM2 
(or anti-NDUFS1) immunoprecipitation, and complexes were analyzed by western blot for 
indicated proteins.  
(T) Representative images of Drosophila expressing an inverted repeat to induce ND75 RNAi 
(c765>ND-75IR) at 18C or transgenic MDM2 (c765>MDM2) at 21C under control of the wing-
specific c765 promoter. “c765gal4/+” is the control wing.  
(U) Livers from wild-type (Wt/Wt), MDM2Tg × 1 allele (Wt/Tg), and MDM2Tg × 2 alleles (Tg/Tg) 
animals were analyzed for mtROS generation, Complex I activity, and H2AX foci. All activities 
were normalized against Wt/Wt (set to 100), and reported as “Relative Units”. 
(V) Total, cytosolic, and mitochondrial fractions from fresh livers harvested from the indicated 
genotypes were analyzed for indicated proteins. Wt/Tg often displayed variable levels of MDM2 
protein, and two examples are shown. “+” indicates a lane with mitochondrial lysate as a positive 
control. 
All data are representative of at least three independent experiments, and reported as  S.D., as 
required. 
 
Figure 5. MDM2 integrates mitochondrial ROS production, genomic stress, and apoptosis 
through disruption of mitochondrial ETC efficiency. 
(A) Pyruvate/malate/ADP-stimulated CI activity (top panel) and FCCP-induced maximal 
respiration (bottom panel) were determined with a Seahorse Analyzer using permeabilized 
H1299 cells treated with buffer, MDM2WT (10 M), or MDM21-101 (10 M). 
(B) H1299 mitochondrial fractions were digitonin extracted, treated with buffer, MDM2WT (10 
M), or MDM21-101 (10 M), and subject to blue native gel electrophoresis (BNGE) for indicated 
ETC assembly, in-gel Complex I (IG-CI), and in-gel Complex II (IG-CII) activities. 
(C) H1299 stably expressing pTRE2-MDM2TetOn were treated with doxycycline (1 g/ml) for 48 
hours in the presence of zVAD-fmk (100 M), mitochondrial fractions were digitonin extracted, 
and analyzed as in B. 
(D) Mitochondrial fractions from H1299 infected with shRNA against NDUFS1 and H1299 
stably expressing pTRE2-MDM2TetOn (treated as in C) were digitonin-extracted, and analyzed by 
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native gel electrophoresis/western blot and SDS-PAGE/western blot for indicated proteins. CII 
and -Actin are loading controls.   
(E) Total protein extracts from the indicated yeast transformants were precipitated and analyzed 
by SDS-PAGE and western blot. 
(F) Indicated transformants were serially diluted and plated on either YDP or YPEG, and 
incubated for 3 days at 30C. W303COA2 is a strain deficient in COA2, an assembly factor for 
cytochrome c oxidase. 
(G) H1299 stably expressing NDI1 was examined with a Seahorse Analyzer for increased CI 
function (top panel), and resistance to rotenone (50 nM, or DMSO) induced loss of clonogenic 
survival (bottom panel). 
(H) Cells in G were transfected with pCMV-MDM2WT (0.1, 0.25, 0.5 g; or pCMV), and whole 
cell lysates were analyzed by western blot for indicated proteins (top panel); or cells were 
cultured for 48 hours and apoptotic cells were quantified (bottom panel). 
(I) H1299 stably expressing pTRE2-TetOn (Control, MDM2WT, or MDM2G58I) treated with 
doxycycline (1 g/ml) for 48 hours in the presence of zVAD-fmk (100 M), or H1299 infected 
with shRNA against NDUFS1, were analyzed with a Seahorse Analyzer for basal and 
Pyruvate/malate/ADP-stimulated (State3) respiration. A representative dataset is shown. 
(J) Data in I, presented as relative units (RU). 
(K) Digitonin-extracted mitochondria from cells described in I were analyzed by IG-CI and IG-
CII assays.  
(L) NADH-stimulated ROS production was measured in digitonin-extracted mitochondria from 
cells described in I (top panel), and following BNGE and elution of CI (bottom panel). 
(M) H1299 were transfected with pCMV-MDM2WT or pCMV-MDM21-101 (0.25 g)  pEGFP-
SOD1 (1 g), cultured for 24 hours, loaded MitoSOX (5 M), and analyzed by flow cytometry. 
(N) H1299 were transfected with pCMV-MDM2WT or pCMV-MDM21-101 (0.25 g), fixed, and 
labeled with an H2AX antibody and DAPI. 100 cells per condition were quantified, in three 
independent. 
(O) H1299 were transfected with pCMV-MDM2WT or pCMV-MDM21-101 (0.25 g)  pEGFP-
SOD1 (1 g), cultured for 48 hours, and apoptotic cells were quantified. 
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(P) H1299 were transfected with pEGFP-SOD1 (1 g), cultured for 48 hours, treated with 
staurosporine (250 nM), and apoptotic cells were quantified 20 hours later. 
(Q - T) Same as M-P, except studies were performed in the presence of MitoQ (5 M). 
All data are representative of at least three independent experiments, and reported as  S.D., as 
required. 
 
 
 
 
  
Elkholi et al., 2018                                                                                                                                               Page 31 
11/30/18 
METHODS  
 
 Reagents.  All cell culture reagents were from Invitrogen; and standard laboratory 
reagents were from Sigma-Aldrich or Fisher Scientific. Drugs were from: ABT737 (Abbvie); 
Antimycin A, Etoposide, FCCP, Nutlin-3a, Staurosporine (Sigma-Aldrich); zVAD-fmk (VWR 
Scientific); MitoQ (MedKoo Biosciences). Antibodies (clone or source): -Actin (C4), BCL-2 
(100), CH11 (Millipore), BAK (G23), BAX (N20), BCL-xL (S18), MDM2 (SMP14), p53 (DO-
1), BCL-2 (100), BIM (22-40), p21 (C19), pH2AX (JBW301), SOD1 (FL154), Cyclin D1 (Cell 
Signaling), Chk1 (FL476, Cell Signaling), Chk1Ser317 (Cell Signaling), Chk1Ser345 (Cell 
Signaling), GST (Z-5), NDI (C-18, Santa Cruz), NDUFS1 (E-8, Santa Cruz), VDAC (FL-283, 
Santa Cruz), Cytochrome c (7H8, Santa Cruz). CellROX and MitoSOXTM were from Thermo 
Fisher Scientific, and Hoechst 33342 was from Anaspec. 
 Cell culture, apoptosis assays, and clonogenic survival. H1299, A549, H23, H460, U-2 
OS, 293T, and MEF lines were cultured in Dulbecco's modified Eagle's medium containing 10% 
heat inactivated fetal bovine serum, 2 mM L-glutamine, 100 U/mL penicillin and 100 g/mL 
streptomycin. SJSA-1 and HCT116 cells were cultured in Roswell Park Memorial Institute 
Medium (RPMI) and McCoy’s 5A Medium, respectively, with the same supplements. For flow 
cytometry-based cell death studies, cells were seeded for 24 hours, treated as described, floating 
and attached cells harvested, labeled with AnnexinV-FITC in binding buffer (10 mM HEPES pH 
7.4, 150 mM NaCl, 5 mM KCl, 1 mM MgCl2, 1.8 mM CaCl2), and analyzed by flow cytometry 
as indicated. For most clonogenic survival studies, cells were seeded for 24 hours, treated as 
indicated for 24 hours before changing the media, and cultured for seven days. For comparisons 
between parental and NDI1 over-expressing clones, cells were treated every two days with either 
DMSO or rotenone until the DMSO-treated cells reached confluency. Colonies were stained with 
0.1% methylene blue and imaged. Colonies were then de-stained (20% methanol in 5% acetic 
acid), and the supernatant was measured for absorption at 668 nm for relative quantification of 
colony numbers. All transfections were performed using Lipofectamine 2000 according to the 
instructions, and empty pcDNA3.1 or pCMV were used as control vectors in all conditions. 
 Plasmids. pCMV-MDM2WT, pCMV-MDM2C464A, and pCMV-HDM2WT were generous 
gifts from Dr. James J. Manfredi (Icahn School of Medicine at Mount Sinai). pcDNA3.1-human 
p53, pcDNA3-hBCL-xL, pcDNA3.1-hMCL-1, pCMV-FADD-DN were gifts from Dr. Douglas 
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Green (St. Jude Children’s Research Hospital). pcDNA3.1-MDM2 truncation mutants were 
obtained from Dr. Christine Eischen (Thomas Jefferson University). MDM2G58A, MDM21-101, 
MDM2NLS, and MDM2NES- were generated by site-directed mutagenesis of pCMV-MDM2WT 
using QuikChange II Site-Directed Mutagenesis Kit (Agilent). SOD1-GFP was a gift from Dr. 
Doris Germain (Icahn School of Medicine at Mount Sinai). shRNA lentiviral plasmids against 
MDMX, Trp53, BAX, and BIM were purchased from Sigma-Aldrich. pGEX-4T3 was used to 
generate pGEX-4T3-MDM2WT and pGEX-4T3-MDM21-101 for recombinant protein expression 
and production using standard 6X-histidine chromatography and gel filtration.  
 Western blot analyses.  Whole cell protein lysates were made from trypsinized cells, 
pelleted, resuspended in RIPA buffer (50 mM Tris, pH 8.0, 150 mM NaCl, 1.0% NP-40, 0.5% 
sodium deoxycholate, 0.1% sodium dodecyl sulfate) supplemented with protease inhibitors 
(HALT, Pierce Biotechnology), incubated on ice for 10 minutes and centrifuged for 10 minutes 
at 21,000 × g. Lysates were then adjusted with RIPA buffer to equal the protein concentrations. 
Proteins (25 - 50 g/lane) were subjected to SDS-PAGE before transferring to nitrocellulose by 
standard western conditions, blocked in 5% milk/TBST and primary antibodies (1:1000 in 
blocking buffer; incubated overnight at 4°C). The secondary antibody (1:5000 in blocking 
buffer) was incubated at 25°C for 1 hour before standard enhanced chemiluminescence 
detection.  
 Immunofluorescence. Cell were plated in NuncTM Lab-Tek™ chamber slides and treated 
as indicated. Cells were washed in 1× PBS then fixed with 4% formaldehyde for 30 minutes at 
room temperature. Cells were washed in 1× PBS and subsequently permeabilized and blocked in 
1× PBS supplemented with 5% normal goat serum and 0.3% TritonX-100 for 60 minutes at 
room temperature. Primary antibodies were diluted in blocking solution as follows: anti-γH2AX 
1:500 (Millipore, JBW301), anti-MDM2 1:250 (SMP-14). Samples were incubated in primary 
antibody overnight at 4ºC. Secondary antibodies: Alexa Fluor® 488 (1:1000, Cell Signaling) and 
Alexa Fluor® (1:200, Cell Signaling) were diluted in blocking buffer and incubated for 90 
minutes at room temperature. Samples were washed three times in 1× PBS then mounted with 
ProLong® Gold Antifade Reagent containing DAPI and cured overnight at room temperature. All 
imaging was performed at 40× magnification with a Zeiss Imager.Z1 equipped with a N-
Achroplan 40×/0.75 water immersion lens and an AxioCAM MRm digital camera; images were 
captured using AxioVision 4.8 and Zeiss Zen software. For quantitative assays, 100 nuclei were 
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counted per condition and reported, in three independent experiments. 
 Mitochondrial ROS production and cellular ROS production analyses by flow cytometry. 
Cells were seeded for 24 hours, and treated as indicated. CellROX (1 M) or MitoSOXTM (1 
M) was added to the media, and the plates were incubated at 37ºC in the dark for 25 minutes. 
The cells were then trypsinized and analyzed by flow cytometry.  
 Microscale thermophoresis. Recombinant GST-tagged MDM2 full length and GST 
protein were N-hydroxysuccinimide (NHS) ester-modified and fluorescently labeled with Alexa 
Fluor 647. GST-MDMWT and GST were incubated with Nutlin-3A (80 μM – 2 nM), p53 peptide 
(a.a. 17-26, ETFSDLWKLL, Anaspec) (125 μM – 15 nM), and NDUFS1 (63 μM – 2 nM) in 
MST buffer (20 mM HEPES pH 7.4, 150 mM NaCl, and 0.05% Tween-20). MicroScale 
Thermophoreses measurements were performed with a NanoTemper Monolith NT.115 using 
standard procedures. 
 Recombinant protein production. GST-MDM2WT, GST-MDM21-101, and GST were 
expressed in E. coli BL21(DE3) Codon Plus (Agilent). Cells were grown in Terrific Broth media 
at 37ºC to an OD600 of ~2-3 before induction with 1 mM isopropyl-1-thio-β-D-galactopyranoside 
and 0.3 mM ZnSO4 for 16 hours at 15ºC. All purification steps were performed at 4ºC. Cells 
were resuspended in lysis buffer (20 mM Tris pH 8.0, 500 mM NaCl, 5% glycerol, and 0.1 mM 
4-(2-Aminoethyl)-benzenesulfonylfluoride and sonicated. Proteins were captured using a 
GSTrap FF column (GE HealthCare), washed in GSTrap FF lysis buffer, and eluted in lysis 
buffer containing 50 mM glutathione (reduced) pH 8.0. Eluted proteins were subjected to size 
exclusion chromatography using a Superdex S200 16/600 column in gel filtration buffer (20 mM 
Tris pH 8.0, 150 mM NaCl, 5% glycerol, and 1 mM TCEP). Positive peak fractions were pooled, 
concentrated to 5 mg/ml using Pierce Protein concentrator 10K (Thermo Scientific), aliquoted, 
flash frozen in liquid nitrogen, and stored at -80ºC. Human GST-NDUFS1 was purified using the 
same protocol. 
 Seahorse bioanalyzer MitoStress analysis. Cells were seeded in 200 l DMEM complete 
media in XF96 plates (Agilent Technologies); plating densities: SJSA-1 4 × 103, H1299 8 × 103, 
MEFs 5 × 103, and treated as indicated. Oxygen consumption rates (OCR) and extracellular 
acidification rates (ECAR) were measured using the XF96 Extracellular Flux Analyzer and the 
XF Cell Mito Stress Test kit. At the end of the assay, media was removed and cells were stained 
with methylene blue, de-stained, and the absorbance was measured at 668 nm using a plate 
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reader (Synergy H1 Hybrid multi-mode micro-plate reader, BioTek). The OCR and ECAR 
measurements were normalized against the cell densities. Each experiment contained three 
independent data points. To measure FCCP-induced maximal respiration in permeabilized cells 
treated with recombinant MDM2, the final concentration of oligomycin was 2 μM.   
Seahorse bioanalyzer complex I activity. H1299 cells were seeded in XFe96 plates 
(15,000 cells/well). Media was removed and cells were washed in 1× Mitochondrial Assay 
Buffer (MAB: 220 mM mannitol, 70 mM sucrose, 10 mM KH2PO4, 5 mM MgCl2, 2 mM 
HEPES, 1 mM EGTA, 0.2% fatty acid free BSA). Cells were permeabilized in 1× MAB 
containing 1 nM plasma membrane permeabilizer (Agilent), and incubated at 37°C without CO2 
for 30 minutes. Baseline OCR measurements were recorded before administration of complex I 
metabolites and recombinant MDM2 protein. Complex I activity was measured by the 
administration of 10 mM pyruvate, 0.5 mM malate, 4 mM ADP ± 10 M GST-MDM2WT or 
GST-MDM21-101.  
 Real-time live-cell analyses. H1299 were seeded at 3 × 103 cells/well in 96-well tissue 
culture-treated plates. Briefly, media was replaced 18 - 24 hours post plating with phenol red-
free media containing the indicated treatments and fluorescently labeled recombinant Annexin V 
(1 g/mL). Immediately following treatment, plates were analyzed in real time by an IncuCyte 
ZOOM (Essen Bioscience, Ann Arbor, MI, USA). Phase contrast and fluorescent images were 
captured at regular intervals using the following IncuCyte ZOOM filter cubes: Green Channel – 
Excitation 460 nm [440,480], Emission 524 nm [504,544]. Experiments utilized potent apoptotic 
inducers (250 nM staurosporine or 100 ng/ml TNFα + 25 g/ml Cycloheximide; data not shown) 
as internal controls to set appropriate Y-axis values. Fluorescent events were analyzed by the 
IncuCyte ZOOM software as previously described (Gelles and Chipuk, 2016). A processing 
definition for Annexin V-FITC-labeled H1299 cells was defined as follows: Channel: Green; 
Top-Hat; Radius: 25 M, Threshold: 3.0 GFU; Edge Sensitivity: -24; Pixel Adjust: 0; Area: >75 
m; Eccentricity: undefined; Mean Intensity: undefined; Integrated Intensity: undefined.  
 Real-time quantitative PCR. Total cellular RNA was extracted using an RNeasy kit 
(Qiagen) according to the manufacturer’s instructions. Total RNA (1 g) was used to synthesize 
first strand cDNA using the SuperScriptTM III First-Strand Synthesis System for RT-PCR 
(Invitrogen). Gene expression was analyzed using the SYBR Green detection system (FastStart 
Universal SYBR Green Master, Roche) and Applied Biosciences ViiATM 7 Real-Time PCR 
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system, using the comparative CT method. The expression of relevant genes was normalized to 
18S and gapdh. The following primer pairs (5’ - 3’) were used: 
 RNA interference. Plasmids for shRNA were purchased from Sigma-Aldrich (MissionR 
shRNA). The pLKO empty vector and scrambled shRNA constructs were kindly provided by the 
laboratory of Dr. E. Premkumar Reddy (Icahn School of Medicine at Mount Sinai). The 293T 
cell line was used to produce retroviral and lentiviral particles for the generation of stable cell 
lines. Virus was harvested at 24 hours and 48 hours, pooled, and 0.45 m filtered. Stable clones 
were generated using puromycin (0.4 - 0.8 g/mL).   
 Mitochondria isolations. As previously described, at least 2 × 15 cm dishes at 90 - 95% 
confluency were used per treatment (Renault et al., 2015). Cells were harvested by 
trypsinization, and pelleted by centrifugation at 1000 × g for 10 minutes. The cell pellet was 
washed once with mitochondrial isolation buffer (MIB: 200 mM mannitol, 68 mM sucrose, 10 
mM HEPES-KOH pH 7.4, 10 mM KCl, 1 mM EDTA, 1 mM EGTA, 0.1% BSA), and 
resuspended in MIB supplemented with protease inhibitors (HALT, Pierce Biotechnology). The 
cell suspension was incubated on ice for 20 minutes, and homogenized using a 2 mL Potter-
Elvehjem dounce. The homogenate was centrifuged for 10 minutes at 800 × g at 4ºC, the 
supernatant collected, and centrifuged again using the same conditions to ensure that no unlysed 
cells or nuclei were present. The resulting supernatant was centrifuged for 10 minutes at 8000 × 
g at 4ºC. The supernatant was collected as the S8 cytosol; the pellet was collected as 
mitochondrial fraction and lysed using RIPA buffer. 
Mitochondrial complex extractions and analyses. Mitochondria were isolated as 
described above, resuspended in extraction buffer (1M 6-amino-hexanoic acid, 50 mM Bis-Tris 
HCl pH 7.0), and solubilized with digitonin (final concentration 6%) on ice for 10 minutes, 
followed by centrifugation at 13,000 × g at 4ºC for 20 minutes. Glycerol (10% final 
concentration) and Coomassie G-250 (0.5% final concentration, only for blue native gel 
electrophoresis). 100 μg of sample/lane was resolved using Criterion TGXTM 4-15% gels (Bio-
Rad) using native conditions. For in-gel CI assays, gels were soaked in 10 ml of 5 mM Tris/HCl 
pH 7.4 containing NTB (25 mg) and 100 l of 10 mg/ml NADH; for in-gel CII assays, gels were 
soaked in 10 ml of 5 mM Tris/HCl pH 7.4 containing NTB (25 mg), 200 l of 1 M sodium 
succinate, and 8 l of 250 mM phenazine methosulfate. All in-gel assays were performed for 30 
minutes at room temperature. For CI superoxide generation measurements, CI (50 g digitonin 
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extract) was stimulated with 20 M NADH in 5 mM Tris/HCl pH 7.4; H2O2 production was 
measured using a standard AmplexRed kit (Invitrogen) supplemented with 40 U/ml human 
erthryocyte SOD (Sigma-Adrich) for 15 minutes at 37ºC. Following BNGE and electro-elution 
of CI, the same assay was performed. All assays are based on published protocols (Wittig et al., 
2007; Lopez-Fabuel et al, 2016). 
 Metaphase chromosome spreads. Cells were seeded for 24 hours before treatment with 
nocodazole (50 ng/mL) for 20 hours. Floating and attached cells were collected and centrifuged 
at 800 × g for 5 minutes. Cells were resuspended in pre-warmed 75 mM KCl and incubated at 
37ºC for 10 minutes with frequent inversions. Samples were centrifuged at 600 × g for 5 
minutes, supernatants removed by inversion, and the pellets resuspended in the remaining 
volume of buffer. Once completely resuspended, cells were fixed by adding ice-cold fixative (3:1 
ratio methanol: glacial acetic acid) in a drop-wise fashion with gentle vortexing. Samples were 
incubated for 10 minutes at room temperature, and then centrifuged at 1000 × g for 5 minutes. 
The fixing steps were then repeated once. The final pellet was resuspended in 0.5 mL of fixative, 
and dropped onto slides ensuring single drops and appropriate spreading on slides. Slides were 
stained with Giemsa Stain for 20 minutes, rinsed, dried, mounted with Permount Medium, and 
dried overnight before microscopy. 
 Drosophila experiments. Flies were reared on standard media at the temperatures 
indicated in each figure. Males and females were assessed separately. Results in the figures 
reflect representative experiments that have been performed independently a minimum of three 
times. To assess genetic modification in the eye, we recombined a UAS MDM2 element with 
GMRgal4 on the second chromosome and crossed balanced flies to control w1118 flies or to 
potential modifiers. Adult eyes of progeny were scored by eye for size, roughness, and 
pigmentation to assess genetic modification compared to controls and then were photographed at 
the same angle and magnification. For scoring, because eyes do not lie flat for quantitative 
measurements, we found side-by-side comparisons of populations to yield the most reliable 
assessment of eye phenotypes. Expressing MDM2 using GMRgal4 substantially decreased 
viability at 30°C. To quantify modification of near lethality, we counted eclosed progeny and 
scored for balancer markers to determine which inherited the balancer and which inherited the 
GMR>MDM2 chromosome for crosses to w1118 and each candidate modifier. Figure 2O indicates 
the number of progeny to eclose and the percent of each genotype expected for Mendelian 
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inheritance. To analyze protein expression, whole larvae were lysed in 1× RIPA buffer, and 
treated as indicated above. 
To assess modification of wing phenotypes, we created a stock with UAS MDM2 and 
c765gal4 over the SM6-TM6B balancer to cross to control w1118 flies or to potential modifiers. 
Adult wings of progeny were photographed at the same magnification and then traced using 
ImageJ software. Flies expressing p35 and MDM2 using c765gal4 were somewhat folded (not 
flat), so the reported measurements reflect only the outline of the wing, not the entire area of 
wing tissue and are therefore an under-estimate. 
Genotypes of flies in the figures are: 
w; GMRgal4/+  (Fig. 2M, 2N; labeled “Control”) 
w; GMRgal4, UAS MDM2/+ (Fig. 2M, 2N; labeled “MDM2”) 
w; GMRgal4, UAS MDM2/+; UAS DIAP1/+ (Fig. 2N) 
w; GMRgal4, UAS MDM2/UAS p35  (Fig. 2N) 
w; GMRgal4, UAS MDM2/+; Df(3L)H99/+  (Fig. 2N) 
w; GMRgal4,UAS MDM2/ GMRgal4,UAS MDM2  (Fig. 2M; labeled “MDM2  2”) 
w; c765gal4/+  (Fig. 4T) 
w; UAS ND-75IR/+; c765gal4/+  (Fig. 4T) 
w; UAS MDM2/+; c765gal4/+  (Fig. 4T) 
w; UAS MDM2/+; c765gal4/UAS DIAP1  (Fig. S2J) 
w; UAS MDM2/UAS p35; c765gal4/+  (Fig. S2J) 
w; UAS MDM2/+; c765gal4/Df(3L)H99  (Fig. S2J) 
Yeast transformation, growth, and expression analyses. W303 yeast were transformed 
with pTEF2 or pTEF-MDM2 plasmids (courtesy Barbara di Ventura, U. Heidelberg) using 
lithium acetate; and transformants were selected using adenine, leucine, histidine, and tryptophan 
on synthetic complete (SC)-glucose agar plates. For growth and expression analyses, colonies 
were isolated, grown in SC-glucose broth supplemented with adenine, leucine, histidine, and 
tryptophan. One absorbance unit (AU) at 600 nm/mL (equivalent to 1.2 × 107 cells/mL) was 
serially diluted 10-fold with sterile water, equal volumes of each dilution were placed on YPD 
and YPEG plates, incubated for 3 days at 30C, and photographed. For protein expression 
analyses, yeast extracts were prepared by incubating 3.6 × 107 cells in Rodel mix (2 M NaOH, 
7% 2-mercaptoethanol, 10 mM PMSF) for 10 minutes on ice; followed by dilution with 0.5 mL 
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water and 25% TCA (final concentration) for 10 minutes on ice. Precipitated proteins were 
pelleted (21,000 × g, 10 minutes, 4C), washed with acetone, and air-dried. Pellets were 
resuspended in 1× Laemmli sample buffer, and heated at 95C for 5 minutes. Equal volumes of 
yeast extracts were analyzed by SDS-PAGE and western blot with anti-MDM2 antibody 
(SMP14) followed by secondary antibody horseradish peroxidase conjugate (Bio-Rad, Hercules, 
CA, USA). Immunoblots were incubated with Super Signal West Pico Chemiluminescent 
Substrate and detected using a Li-Cor blot scanner.   
Transgenic MDM2 mice. Transgenic MDM2 mice were obtained from Dr. Stephen N. 
Jones via Dr. James J. Manfredi and have been previously described (Jones et al., 1998). All 
animal experiments were performed in accordance with protocols approved by the Icahn School 
of Medicine at Mount Sinai Institutional Animal Care and Use Committee. Tail DNA and liver 
RNA was isolated using Qiagen DNeasy and RNeasy kits, respectively. Genotyping was 
performed using standard qPCR-based methods (Forward primer: 5' AGG ATC TCC TGT CAT 
CTC ACC TTG CTC CTG 3'; Reverse primer: 5' AAG AAC TCG TCA AGA AGG CGA TAG 
AAG GCG 3'). Livers were fixed in formalin, and tissues were embedded in OCT compound and 
frozen, or processed and embedded in paraffin, sectioned, and stained as indicated. Whole cell 
lysates were generated by homogenizing 100 mg of tissue in MIB, adding an equal volume of 
RIPA buffer, incubating on ice for 20 minutes, and insoluble material was pelleted (21,000 × g, 
10 minutes, 4C). Mitochondria were isolated as indicated above, and subjected to BNGE, CI 
assays, and superoxide generation measurements. 
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SUPPLEMENTAL INFORMATION AND LEGENDS 
 
Figure S1. Experiments related to figure 1. 
(A) Whole cell lysates from H1299 stably expressing MDMX RNAi were analyzed by SDS-
PAGE and western blot for indicated proteins. -Actin is the loading control. 
(B - C) H1299 were transfected with pcDNA.MDMX (0, 0.1, 0.2, 0.4, 0.8 g) for 24 hours in the 
presence of zVAD-fmk (100 M); total RNA and protein were analyzed by qPCR and western 
blot for MDMX expression. CT are untreated cells. The DNA mass was scaled for western blot 
detection of protein, and reduced for 96 well format IncuCyte experiments. 
(D - F) H1299 were transfected with indicated MDM2, MDMX, and p53 plasmids, and the 
kinetics of cell death were detected using an IncuCyte Zoom. 
 
Figure S2. Experiments related to figure 2. 
(A - B) H1299 stably expressing BIM or BAX RNAi were generated. Total RNA and protein 
were analyzed by qPCR and western blot for BIM (A) and BAX (B) knock-down efficiency, 
respectively.  
(C) H1299 were transfected with pcDNA.MDM2WT (0.5 g), and CHAPS lysates were subjected 
to immunoprecipitation with the anti-BAX clone 6A7. Total cell lysates were also analyzed by 
SDS-PAGE and western blot for indicated proteins. -Actin is the loading control. 
(D - E) H1299 stably expressing BAK, BID, or PUMA RNAi were generated. Total RNA and 
protein were analyzed by qPCR (D) and western blot (E) for knock-down efficiency, 
respectively.  
(F - G) Indicated control (pLKO) and stable RNAi lines from D-E were transfected with 
pcDNA.MDM2 (F) or pcDNA.control (G) and the kinetics of cell death were detected using an 
IncuCyte Zoom. 
(H) Whole larval lysates were analyzed by SDS-PAGE and western blot for indicated proteins to 
confirm MDM2 expression. 
(I) Representative images of Drosophila expressing transgenic MDM2 under control of the eye-
specific GMR promoter (GMR>MDM2). The Gal4/UAS system is temperature sensitive, and 
animals were reared at indicated temperatures to increase MDM2 levels. Images shown are 
female eyes. Fly from 30C is a dissected pharate adult. 
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(J) Representative images of Drosophila expressing transgenic MDM2 under control of the 
wing-specific GMR promoter (c765>MDM2) with H99 deletion, or co-expressing DIAP1 or p35. 
“c765gal4/+” is the control wing. Studies were performed at 21C.  
 
Figure S3. Experiments related to figure 4. 
(A) H1299 were untreated (Control), mock transfected (No DNA transfection but 
Lipofectamine2000), or transfected with empty pCMV (0.25 g), cultured for 24 hours, and 
subjected to Seahorse XF Cell Mito Stress analysis.  
(B) Whole cell lysates from U-2OS and SJSA-1 cells were analyzed by SDS-PAGE and western 
blot for indicated proteins.  
(C - D) U-2 OS were treated with Nutlin-3A (1 M) for 48 hours, and subjected to Seahorse XF 
Cell Mito Stress analysis. A representative MitoStress assay (C) and endpoint data are shown 
(D).  
(E - G) U-2 OS and SJSA-1 were treated with Nutlin-3A (1 M) for indicated times. Total RNA 
and protein were analyzed by qPCR (E-F) and western blot (G) for MDM2 induction. 
 
Figure S4. Additional experiments related to figure 4. 
(A) 20 ng of GST-MDM2WT was loaded with endogenous NDUFS1 in PBS, captured on Protein 
A beads containing anti-MDM2 (clone SMP14), and incubated in the presence of 6HIS-p53 (10, 
25, 50 ng) for 1 hour at RT before washing and analyses via SDS-PAGE and western blot for 
indicated proteins. GST-MDM2 + p53 (no NDUFS1) demonstrates maximal binding. VH and VL 
are the heavy and light chains from the SMP14 antibody, respectively. 
(B) SDS-PAGE and Coomassie Blue Staining of GST-MDM2WT and GST-MDM2C464A protein 
fractions following GSH-Sepharose chromatography. Indicated fractions (white hatched box) 
were combined and utilized. 
(C) Combined fractions from B were analyzed by SDS-PAGE and western blot. 
(D) H1299 were transfected with pCMV-MDM2WT or pCMV-MDM2C464A (1 g each) for 24 
hours in the presence of zVAD-fmk (100 M), cytosolic extracts were subjected to anti-MDM2 
immunoprecipitation, and complexes were analyzed by western blot for indicated proteins.  
(E) H1299 were transfected with indicated MDM2 mutants (1 g each), cultured for 24 hours in 
the presence of zVAD-fmk (100 M), and cytosolic extracts were subjected to anti-MDM2 
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immunoprecipitation, and complexes were analyzed by western blot for indicated proteins. 
Whole cell lysates were also analyzed to ensure NDUFS1 was equally expressed in all 
transfections. 
(F) H1299 were transfected with indicated pCMV MDM2 variants (0.25 g) in the presence of 
zVAD-fmk (100 M), cultured for 24 hours, fixed, and stained for MDM2 localization. Scale bar 
= 10 m. 
(G) H1299 were transfected with pCMV-MDM2WT or pCMV-MDM2G58I (1 g each) for 24 
hours in the presence of zVAD-fmk (100 M). Cytosolic, mitochondrial, and total cell lysates 
were analyzed by SDS-PAGE and western blot for indicated proteins. 
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